AstraZeneca chief executive Pascal Soriot warned European governments they may withhold new medicines if pricing rules stay unchanged. He linked the threat to the US trade deal that obliges the United States to open its market to European drugs. Soriot said the agreement forces Europe to match U.S. spending on innovative therapies.

The warning follows years of pressure from health ministries to curb drug price inflation. AstraZeneca, which expects its pipeline to generate over $30 billion in sales this decade, argues that stricter caps would shrink profit margins and delay launch of breakthrough treatments. European payers risk losing access to next‑generation oncology and vaccine products unless they raise reimbursement levels.

Investors see the standoff as a test of Europe’s willingness to fund high‑cost innovation. If governments cling to low‑price policies, AstraZeneca could pause introductions, squeezing market share to rivals willing to accept tighter pricing. The episode underscores how trade commitments can reshape pharmaceutical pricing strategies across the Atlantic.

Regulators in France, Germany and the UK have already signaled tougher price negotiations, prompting industry calls for a coordinated EU response. Soriot’s ultimatum puts pressure on policymakers to balance budget constraints with the need to keep Europe at the forefront of medical breakthroughs in the coming years.